Three Swiss biotechs promote from within
Avrion Therapeutics named co‑founder Maximilien Murone interim CEO, with former CEO Harald Petry becoming chairman and chief scientific officer; InSphero promoted Olivier Frey to combined COO/CTO; Opterion Health appointed Ulrike Maria Grimm as Chief Development Officer. These internal promotions illustrate a trend of succession planning within Swiss biotech firms.
Avrion Therapeutics named co‑founder Maximilien Murone interim CEO, with former CEO Harald Petry becoming chairman and chief scientific officer; InSphero promoted Olivier Frey to combined COO/CTO; Opterion Health appointed Ulrike Maria Grimm as Chief Development Officer. These internal promotions illustrate a trend of succession planning within Swiss biotech firms.
It highlights the depth of Swiss biotech talent, a key component of the country’s broader AI‑driven life‑science ecosystem.
Original source record. Open the original record to verify the underlying announcement.